Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have limited response rates in selected patients and can cause potentially life-threatening immune-related adverse events (irAEs). This underscores the urgent need for the development of biomarkers predictive of ICI response. Pre-existing autoantibodies (AAbs) have been linked with responses to ICIs and the development of irAEs. We conducted AAb profiling to assess associations between baseline AAbs and clinical benefit (CB) in patients with rare tumors treated with anti-programmed cell death protein 1-based therapy.

Patients and methods

We conducted AAb profiling using Oncimmune's SeroTag multiplex antibody discovery technology and immune oncology array containing 1168 antigens. The study included 41 patients with rare tumors w

SUBMITTER: Derbala MH 

PROVIDER: S-EPMC12345252 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature